Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02538627 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
A Phase 1 study, sponsored by Merrimack Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT02538627 is a Phase 1 study that was terminated before completion, run by Merrimack Pharmaceuticals. The registered enrollment target is 5 participants.
The verdict
NCT02538627, a Phase 1 study, was terminated before completion, sponsored by Merrimack Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a Phase 1 open-label, dose-escalation trial using "3+3" design, evaluating MM-151 co-administration with MM-121, MM-141, and trametinib at varying dose levels.
Interventions
- DRUG trametinib
- DRUG MM-121
- DRUG MM-141
- DRUG MM-151
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2015-08 |
| Est. Completion | 2016-10-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02538627
The ClinicalTrials.gov registry entry for NCT02538627 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merrimack Pharmaceuticals, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which trametinib is the first listed.
NCT02538627 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02538627 about?
NCT02538627 is a clinical study titled "Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib". This is a Phase 1 open-label, dose-escalation trial using "3+3" design, evaluating MM-151 co-administration with MM-121, MM-141, and trametinib at varying dose levels.
What is the current status of trial NCT02538627?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2015-08. Estimated completion is 2016-10-05.
What interventions are being tested in trial NCT02538627?
The interventions under investigation include: trametinib (DRUG), MM-121 (DRUG), MM-141 (DRUG), MM-151 (DRUG).
Who is sponsoring clinical trial NCT02538627?
This trial is sponsored by Merrimack Pharmaceuticals, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.